The Importance of Thiol/Disulfide Homeostasis-and Ischemia-Modified Albumin Levels in Acute Coronary Syndrome and Their Relationship with Angiographic Scoring Systems


Abstract views: 102 / PDF downloads: 51

Authors

DOI:

https://doi.org/10.5152/eurjther.2020.20021

Keywords:

Thiol/disulfide homeostasis, ischemia-modified albumin, acute coronary syndrome

Abstract

Objective: The objective of this study was to investigate the differences in thiol/disulfide homeostasis- and ischemia-modified albumin (IMA) levels that are known to be associated with oxidative damage in patients with acute coronary syndrome between ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction/unstable angina pectoris (NSTEMI/USAP) groups and their relationships with angiographic scoring systems.
Methods: A total of 142 patients were included in this study, with 49 in group 1 (STEMI) and 93 in group 2 (NSTEMI/USAP). Thiol/disulfide homeostasis was determined using a recently developed novel method. We investigated whether thiol/disulfide homeostasis and parameters such as IMA, troponin I, and creatine kinase MB fraction levels were associated with Gensini, and Syntax I and II scores, which are angiographic scoring systems.
Results: The native and total thiol levels were found to be statistically significantly lower in the STEMI group than in the NSTEMI/USAP group (both, p < 0.05). The serum IMA levels were statistically significantly higher in group 1 (0.59±0.12 vs 0.46±0.23 absorbance units, p<0.05). A significant positive correlation was found between the IMA and peak troponin I levels.
Conclusion: Thiol/disulfide homeostasis was shifted in favor of disulfide in the STEMI group, indicating a significant correlation between increased myocardial damage and disulfide. Similarly, the significantly higher IMA levels and positive correlation between IMA and peak troponin I in the STEMI group indicate its vulnerability in the infarcted myocardium area in addition to its vulnerability known in ischemia.

Metrics

Metrics Loading ...

References

Allen EM, Mieyal JJ. Protein-thiol oxidation and cell death: regulatory role of glutaredoxins. Antioxid Redox Signal 2012; 17: 1748-63.

Jaganjac M, Cipak A, Schaur RJ, Zarkovic N. Pathophysiology of neutrophil-mediated extracellular redox reactions.

Vassalle C, Pratali L, Boni C, Mercuri A, Ndreu R. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin Biochem 2008; 41: 1162-67.

Sezen Y, Bas M, Polat M, Yildiz A, Buyukhatipoglu H, Kucukdurmaz Z, et al. The relationship between oxidative stress and coronary artery ectasia. Cardiol J 2010; 17: 488-94.

Levy Y, Bartha P, Ben-Amotz A, Gerald Brook J, Dankner G, Lin S, et al. Plasma antioxidants and lipid peroxidation in acute myocardial infarction and thrombolysis. J Am Coll Nutr 1998; 17: 337-41.

Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox processes. Free Radic Biol Med 2013; 65: 244-53.

Jones DP, Liang Y. Measuring the poise of thiol/disulfide couples in vivo. Free Radic Biol Med 2009; 47: 1329-38.

Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem 2014; 47: 326-32.

Altıparmak IH, Erkuş ME, Sezen H, Demirbağ R, Günebakmaz O, Kaya Z et al. The relation of serum thiol levels and thiol/disulphide homeostasis with the severity of coronary artery disease. Kardiol Pol. 2016; 74: 1346-53.

Kundi H, Ates I, Kiziltunc E, Cetin M, Cicekcioglu H, Neselioglu S, et al. A novel oxidative stress marker in acute myocardial infarction; thiol/disulphide homeostasis. Am J Emerg Med 2015; 33: 1567-71.

Kundi H, Erel Ö, Balun A, Çiçekçioğlu H, Cetin M, Kiziltunç E, et al. Association of thiol/disulfide ratio with SYNTAX score in patients with NSTEMI. Scand Cardiovasc J 2015; 49: 95-100.

Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med 2011; 49: 177-84.

Gaze DC. Ischemia modified albumin: a novel biomarker for the detection of cardiac ischemia. Drug Metab Pharmacokinet 2009; 24: 333-41.

Worster A, Devereaux PJ, Heels-Ansdell D, Guyatt GH, Opie J, Mookadam F, et al. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. CMAJ 2005; 172: 1685-90.

Filippi C, Yoon S, Ro A. Early detection of myocardial ischemia by a novel blood based biomarker: the kinetics of ischemia modified albumin. J Am Coll Cardiol 2003; 41:6.

Anwaruddin S, Januzzi JL Jr, Baggish AL, Lewandrowski EL, Lewandrowski KB. Ischemia-modified albumin improves the usefulness of standard cardiac biomarkers for the diagnosis of myocardial ischemia in the emergency department setting. Am J Clin Pathol 2005; 123: 140-5.

Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC. Role of ischemia modified albumin a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004; 21: 29-34.

Roy D, Quiles J, Aldama G, Sinha M, Avanzas P, Arroyo-Espliguero R, et al. Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or nondiagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol 2004; 97: 297-301.

Gurumurthy P, Borra SK, Yeruva RK, Victor D, Babu S, Cherian KM. Estimation of Ischemia Modified Albumin (IMA) Levels in Patients with Acute Coronary Syndrome. Indian J Clin Biochem 2014; 29: 367-71.

Bhagavan NV, M Lai E, Rios PA, Yang J, Ortega-Lopez, Shinoda H, et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581-5.

Wudkowska A, Goch J, Goch A. Ischemia-modified albumin in differential diagnosis of acute coronary syndrome without ST elevation and unstable angina pectoris. Kardiol Pol 2010; 68: 431-7.

Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.

Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet 2013; 381: 639-50.

Roques F, Michel P, Goldstone AR, Nashef SA. The logistic EuroSCORE. Eur Heart J 2003; 24: 881-82.

Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.

David Bar-Or, Edward Lau, James V. Winkler. A novel assay for cobalt-albumin binding and its potential as a marker for Myocardial ischemia-a preliminary report. The Journal of Emergency Medicine 2000;19: 4311-315.

Zurawska-Płaksej E, Grzebyk E, Marciniak D, Szymańska- Chabowska A, Piwowar A. Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome. J Endocrinol Invest 2014; 37: 819-27.

Akkuş O, Topuz M, Koca H, Harbalioğlu H, Kaypaklı O, Kaplan M, et al. The relationship between low thiol levels and major adverse cardiovascular events after primary percutaneous coronary intervention in patients with STEMI. Turk Kardiyol Dern Ars 2018; 46: 248-59.

Chawla R, Goyal N, Calton R, Goyal S. Ischemia modified albumin: A novel marker for acute coronary syndrome. Indian J Clin Biochem 2006; 21: 77-82.

Kazanis K, Dalamaga M, Nounopoulos C, Manolis AS, Sakellaris N, Jullien G, et al. Ischemia modified albumin, high-sensitivity C-reactive protein and natriuretic peptide in patients with coronary atherosclerosis. Clin Chim Acta 2009; 408: 65-9.

Maneewong K, Mekrungruangwong T, Luangaram S, Thongsri T, Kumphune S. Combinatorial determination of ischemia modified albumin and protein carbonyl in the diagnosis of nonST-elevation myocardial infarction. Indian J Clin Biochem 2011; 26: 389-95.

Fairclough E, Cairns E, Hamilton J, Kelly C. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond) 2009; 9: 30-3.

Çınar T, Çağdaş M, Rencüzoğulları İ, Karakoyun S, Karabağ Y, Yesin M, et al. Prognostic efficacy of C-reactive protein/albumin ratio in ST elevation myocardial infarction. Scand Cardiovasc J 2019; 53: 83-90.

Downloads

Published

2020-12-01

How to Cite

Ermiş, E., Hanikoğlu, F., Uçar, H., Allahverdiyev, S., Yıldırım, E., Neşelioğlu, S., Erel, Özcan, Dokur, M., & Cengiz, M. (2020). The Importance of Thiol/Disulfide Homeostasis-and Ischemia-Modified Albumin Levels in Acute Coronary Syndrome and Their Relationship with Angiographic Scoring Systems. European Journal of Therapeutics, 26(4). https://doi.org/10.5152/eurjther.2020.20021

Issue

Section

Original Articles